Private Markets, Angel and Secondary Investing, Sacra

Sacra

Bringing transparency to private markets so investors, founders, and employees can build on conviction.

Sacra delivers deeply researched insights on the private companies shaping tomorrow's markets. By surfacing the data, context, and operator perspective that are missing from private markets today, we help secondary buyers and sellers price equity accurately and unlock liquidity for the people building these businesses.

Private Markets, Angel and Secondary Investing

Bringing transparency to private markets so investors, founders, and employees can build on conviction. Sacra delivers deeply researched insights on the private companies shaping tomorrow's markets. By surfacing the data, context, and operator perspective that are missing from private markets today, we help secondary buyers and sellers price equity accurately and unlock liquidity for the people building these businesses.

Private Capital Markets

<ul><li>Pathos raised a $365M Series D in May 2025 at approximately $1.6B post-money valuation.</li><li>PathOS has three connected components.</li><li>Pathos's current clinical pipeline includes pocenbrodib, a CBP/p300 inhibitor being developed across prostate, breast, and multiple myeloma, and P-500, a brain-penetrant PRMT5 inhibitor for advanced solid tumors.</li></ul>

Pathos raised a $365M Series D in May 2025 at approximately $1.6B post-money valuation.PathOS has three connected components.Pathos's current clinical pipeline includes pocenbrodib, a CBP/p300 inhibitor being developed across prostate, breast, and multiple myeloma, and P-500, a brain-penetrant PRMT5 inhibitor for advanced solid tumors.

Pathos

Primer: Pathos - 03 Aug 2026